Neumora Faces MDD Setback, Pivots on Key Neuroscience Programs

Ticker: NMRA · Form: 10-K · Filed: Mar 30, 2026 · CIK: 0001885522

Sentiment: mixed

Topics: Biotechnology, Neuroscience, Clinical Trials, Major Depressive Disorder, Alzheimer's Disease, Schizophrenia, Drug Development, Kappa Opioid Receptor Antagonist

Related Tickers: NMRA, AMGN, VYGR, SAGE, AXSM

TL;DR

**NMRA is a high-risk bet on neuroscience, with the navacaprant MDD program on thin ice, making upcoming Q2 2026 data a make-or-break moment for this speculative biotech.**

AI Summary

Neumora Therapeutics, Inc. (NMRA) is a clinical-stage biopharmaceutical company focused on neuroscience. The company is advancing several programs, including navacaprant for Major Depressive Disorder (MDD), NMRA-511 for agitation associated with Alzheimer's disease (AD), NMRA-898 for schizophrenia, and NMRA-215 for obesity. In January 2025, the KOASTAL-1 Phase 3 study for navacaprant did not meet its primary or key secondary endpoints, though it was safe and well-tolerated. Following this, Neumora adjusted the KOASTAL-2 and -3 studies, which are fully enrolled with over 400 patients each, and expects topline data in Q2 2026. NMRA-511 showed clinically meaningful effects in Phase 1b for AD agitation, with further MAD extension data expected in H2 2026 and a Phase 2 study initiating in Q1 2027. NMRA-898, designated as the lead M4 program in March 2026, demonstrated an 80-100-hour half-life in Phase 1, supporting once-daily dosing, with MAD data anticipated in H2 2026. The company's market value of common stock held by nonaffiliates was approximately $63.3 million as of June 30, 2025.

Why It Matters

Neumora's 10-K reveals a critical juncture for its pipeline, particularly after the navacaprant KOASTAL-1 failure. For investors, the success of the adjusted KOASTAL-2 and -3 studies in Q2 2026 is paramount, as is the progress of NMRA-511 and NMRA-898, which could define the company's future valuation and competitive standing against other CNS drug developers. Employees and customers are directly impacted by the efficacy and safety of these novel therapies, especially in underserved areas like MDD, AD agitation, and schizophrenia. The broader market watches Neumora's 'precision neuroscience approach' as a bellwether for targeted drug development in complex neurological disorders, potentially shifting treatment paradigms if successful.

Risk Assessment

Risk Level: high — The company is a clinical-stage biopharmaceutical company with no approved products, meaning no revenue from product sales. The failure of the navacaprant KOASTAL-1 Phase 3 study in January 2025 to meet its primary and key secondary endpoints highlights significant clinical development risk. The aggregate market value of common stock held by nonaffiliates was approximately $63.3 million as of June 30, 2025, indicating a relatively small market capitalization for a company with multiple late-stage clinical programs, suggesting high volatility and sensitivity to clinical trial outcomes.

Analyst Insight

Investors should exercise extreme caution and await the Q2 2026 topline data for KOASTAL-2 and -3 before considering any significant position. Given the prior Phase 3 failure and the company's clinical-stage status, this stock is highly speculative and suitable only for investors with a high-risk tolerance and a deep understanding of biotech development cycles.

Financial Highlights

debt To Equity
0.0
revenue
$0
operating Margin
N/A
total Assets
$378.0 million
total Debt
$0
net Income
$-230.5 million
eps
$-1.27
gross Margin
N/A
cash Position
$296.1 million
revenue Growth
N/A

Key Numbers

Key Players & Entities

FAQ

What were the key financial results for Neumora Therapeutics in the fiscal year ended December 31, 2025?

The provided 10-K excerpt does not contain specific revenue or net income figures for the fiscal year ended December 31, 2025. However, it notes that the aggregate market value of common stock held by nonaffiliates was approximately $63.3 million as of June 30, 2025.

What is the current status of Neumora's navacaprant program for Major Depressive Disorder?

The navacaprant KOASTAL-1 Phase 3 study, reported in January 2025, did not achieve its primary or key secondary endpoints. However, Neumora made adjustments to the ongoing KOASTAL-2 and -3 studies, which are fully enrolled with over 400 patients each, and expects joint topline data in the second quarter of 2026.

What is NMRA-511 being developed for and what are its upcoming milestones?

NMRA-511 is a V1aR antagonist being developed for the treatment of agitation associated with dementia due to Alzheimer's disease. Phase 1b results in Q1 2026 showed clinically meaningful effects. Neumora plans to report multiple ascending dose (MAD) extension data in the second half of 2026 and initiate a Phase 2 study in Q1 2027.

Which program has Neumora designated as its lead M4 franchise candidate and why?

In March 2026, Neumora designated NMRA-898 as the lead program in its M4 franchise. This decision was based on promising Phase 1 single ascending dose study results, including an approximately 80-100-hour half-life in humans, supporting once-daily dosing, and exposure-dependent increases in heart rate indicating target engagement.

What are the main risks associated with investing in Neumora Therapeutics?

Key risks include the inherent uncertainties of clinical-stage drug development, as evidenced by the navacaprant KOASTAL-1 Phase 3 failure. The company has no approved products and relies on successful clinical trials and regulatory approvals for future revenue. Geopolitical conflicts, general economic conditions, and the ability to secure additional financing also pose risks.

How does Neumora's 'precision neuroscience approach' aim to improve drug discovery?

Neumora aims to redefine neuroscience drug development by using a 'precision neuroscience approach' to bring forward novel therapies with brain-penetrant chemistry. This approach seeks to reduce the time and increase the likelihood of success in research and development compared to traditional drug discovery paradigms, by targeting novel mechanisms of action for underserved diseases.

What is the significance of the GBA1 gene and GCase in Neumora's pipeline?

The GBA1 gene, which codes for the enzyme glucocerebrosidase (GCase), is the single largest genetic risk factor for Parkinson's Disease (PD). Neumora's NMRA-GCase program is an activator focused on elevating GCase activity for PD treatment, as GCase deficiencies lead to lysosomal dysfunction, a factor in approximately 10% of PD patients.

When is Neumora Therapeutics expected to file its proxy statement for the 2026 Annual Meeting of Shareholders?

Neumora Therapeutics is expected to file its proxy statement for the 2026 Annual Meeting of Shareholders no later than 120 days after the close of its fiscal year ended December 31, 2025.

What is the potential market size for navacaprant if approved for Major Depressive Disorder?

Neumora estimates that there are over 21 million adults in the United States diagnosed with Major Depressive Disorder. Of these, 85% either do not receive pharmacological treatment or fail to achieve remission with first-line therapies, indicating a significant unmet medical need and potential market for navacaprant if approved.

What is the role of CK1 in Amyotrophic Lateral Sclerosis (ALS) and Neumora's approach?

CK1 (casein kinase 1 isoform delta) is a kinase identified as a proximal upstream regulator of TDP-43 phosphorylation, a key driver of pathology in approximately 95% of sporadic ALS cases. Neumora's NMRA-CK1 program is a CK1 inhibitor in preclinical development, aiming to reduce TDP-43 phosphorylation and slow disease progression in ALS.

Risk Factors

Industry Context

The neuroscience drug development landscape is characterized by high unmet needs and significant scientific challenges. Companies like Neumora are focused on developing novel therapies for complex neurological and psychiatric disorders, including Major Depressive Disorder and Alzheimer's disease. The industry is highly competitive, with both large pharmaceutical companies and smaller biotechs vying for breakthroughs. Regulatory hurdles and the high cost of clinical trials are significant factors influencing success.

Regulatory Implications

Neumora's drug candidates are subject to rigorous review by regulatory bodies such as the FDA. The failure of the KOASTAL-1 study highlights the inherent risks in clinical development and the stringent requirements for demonstrating efficacy and safety. Any delays or setbacks in regulatory submissions or approvals for NMRA-511, NMRA-898, or other pipeline assets could materially impact the company's future.

What Investors Should Do

  1. Monitor Q2 2026 topline data for KOASTAL-2 and -3 studies.
  2. Evaluate H2 2026 data readouts for NMRA-511 and NMRA-898.
  3. Assess future financing needs and runway.
  4. Track competitive developments in the neuroscience space.

Key Dates

Glossary

Clinical-stage biopharmaceutical company
A company focused on developing new drugs that are currently in clinical trials, meaning they have moved beyond laboratory research and are being tested in humans. (Neumora is in this stage, indicating significant development risk and potential for future revenue if drugs are approved.)
Major Depressive Disorder (MDD)
A common and serious mood disorder characterized by persistent sadness and loss of interest, affecting daily life. (This is the target indication for Neumora's lead drug candidate, navacaprant.)
Alzheimer's disease (AD)
A progressive neurodegenerative disease that causes brain cells to degenerate and die, leading to dementia. (Neumora is developing NMRA-511 for agitation associated with AD.)
Phase 3 study
The final stage of clinical trials before a drug can be submitted for regulatory approval, involving a large number of patients to confirm efficacy and safety. (The failure of the KOASTAL-1 Phase 3 study for navacaprant is a significant event for Neumora.)
Topline data
The primary results of a clinical trial, typically focusing on the main efficacy and safety endpoints. (Investors closely watch topline data readouts for indications of a drug's potential success or failure.)
Half-life
The time required for a substance (like a drug) to lose half of its pharmacological or radiological activity. (The 80-100 hour half-life of NMRA-898 supports the potential for convenient once-daily dosing.)
Market value of common stock held by nonaffiliates
The total market value of a company's shares held by investors who are not company insiders (like executives or major shareholders). (This figure ($63.3 million as of June 30, 2025) provides an indication of the company's public market valuation.)
Net loss
The amount by which total expenses exceed total revenues over a specific period. (Neumora has a history of net losses due to significant R&D investments, which is typical for clinical-stage biotechs.)

Year-Over-Year Comparison

This analysis is based on a single 10-K filing and does not have comparative data from a previous year's filing. Therefore, a comparison of key metrics like revenue growth, margin changes, or new risks cannot be provided.

Filing Stats: 4,388 words · 18 min read · ~15 pages · Grade level 16.3 · Accepted 2026-03-30 07:07:29

Key Financial Figures

Filing Documents

Business

Business 1 ITEM 1A.

Risk Factors

Risk Factors 20 ITEM 1B. Unresolved Staff Comments 74 ITEM 1C. Cybersecurity 74 ITEM 2.

Properties

Properties 75 ITEM 3.

Legal Proceedings

Legal Proceedings 75 ITEM 4. Mine Safety Disclosures 75 PART II ITEM 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 76 ITEM 6. Reserved 76 ITEM 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 77 ITEM 7A.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 87 ITEM 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 88 ITEM 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 119 ITEM 9A.

Controls and Procedures

Controls and Procedures 119 ITEM 9B. Other Information 119 ITEM 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 120 PART III ITEM 10. Directors, Executive Officers and Corporate Governance 120 ITEM 11.

Executive Compensation

Executive Compensation 120 ITEM 12.

Security Ownership of Certain Beneficial Owners and Management Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management Related Stockholder Matters 120 ITEM 13. Certain Relationships and Related Party Transactions, and Director Independence 120 ITEM 14. Principal Accountant Fees and Services 120 PART IV ITEM 15. Exhibits 121 ITEM 16. Form 10-K Summary 122

Signatures

Signatures 123 i Table of Contents Special Note Regarding Forward-Looking Statements This Annual Report on Form 10-K contains forward-looking statements concerning our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business, operations and financial performance and condition. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that are in some cases beyond our control and may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "aim," "anticipate," "assume," "believe," "contemplate," "continue," "could," "due," "estimate," "expect," "goal," "intend," "may," "objective," "plan," "predict," "potential," "positioned," "seek," "should," "target," "will," "would," and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. These forward-looking statements include, but are not limited to, statements about: our expectations regarding the potential market size and size of the potential patient populations for our product candidates and any future product candidates, if approved for commercial use; our clinical and regulatory development plans including any related anticipated program milestones; the ability of our clinical trials to demonstrate safety and efficacy of our product candidates, and other positive results; our expectations with regard to the results of our clinical studies, preclinical studies and research and development programs, including the timing and availability of data from such studies

B usiness

ITEM 1. B usiness. Overview We are a clinical-stage biopharmaceutical company founded to confront the greatest medical challenges of our generation by bringing forward the next generation of novel therapies with brain-penetrant chemistry that offer improved treatment outcomes and quality of life for patients. Our therapeutic pipeline currently consists of programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases. We are advancing a Phase 3 program for navacaprant, a novel once-daily oral kappa opioid receptor ("KOR") antagonist that is being developed for the treatment of major depressive disorder ("MDD"), which we believe has the potential to provide significant advantages relative to the standard of care, if approved. We are also advancing NMRA-511, a highly selective, novel antagonist of the vasopressin 1a receptor ("V1aR") being developed for the treatment of agitation associated with dementia due to Alzheimer's disease ("AD"). Beyond navacaprant and NMRA-511, Neumora is advancing NMRA-898, a novel M4 PAM with potential best in class pharmacology for the treatment of schizophrenia. Additionally, Neumora is developing NMRA-215, a highly brain-penetrant, oral NLRP3 inhibitor for the treatment of obesity. We expect several updates from these programs throughout 2026, including to report Phase 3 KOASTAL-2 and -3 topline data in the second quarter of 2026, report MAD extension data with NMRA-511 in the second half of 2026, and to report multiple ascending dose ("MAD") data with NMRA-898 in the second half of 2026. Our Product Candidates We have rapidly scaled our pipeline through both internal discovery capabilities and business development activities. Our therapeutic pipeline comprises programs for neurodegenerative diseases, neuropsychiatric diseases, and metabolic disorders, each targeting a novel mechanism of action. The current pipeline is shown in the table below. ALS = Amyotrophic lateral sclerosis; CK1= Cas

View Full Filing

View this 10-K filing on SEC EDGAR

View on Read The Filing